The study included more than 500 patients with recurrent ovarian cancer and found that both women with and without a BRCA gene mutation — which helps suppress tumors and make women more treatable — responded positively to the drug.
In patients with a BRCA mutation, progression-free survival for those treated with niraparib was 21 months, compared to 5.5 months for those on a placebo. Patients without the BRCA mutation had a progression-free survival of 9.3 months compared to 3.9 months for those on the placebo.
Researchers said data from the study increases the likelihood that niraparib will be used as a first line treatment for women with ovarian cancer and BRCA-related breast cancer.
Stocks of the Waltham, Mass.-based drugmaker more than doubled to $77 a share in response to news of the trial’s results.
More articles on the drug market:
Viewpoint: 4 reasons the FDA should ditch the pass/fail drug approval process
Pfizer to build $350M biotech center in China
Novartis partners with Xencor to develop bispecific antibodies
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
